Orionis Biosciences

Orionis Biosciences

Biotechnology, 950 Winter St, Waltham, , 2451, Massachusetts, United States, 11-50 Employees

orionisbio.com

  • facebook
  • twitter
  • LinkedIn

Who is ORIONIS BIOSCIENCES

Orionis Biosciences is a life sciences company pioneering technological innovation in genome-scale drug discovery and tunable molecular design of novel therapeutic drug modalities. Our te...

Read More

map
  • 950 Winter St, Waltham, Massachusetts, 2451, United States Headquarters: 950 Winter St, Waltham, Massachusetts, 2451, United States
  • 2015 Date Founded: 2015
  • 11-50 Employees: 11-50
  • dollar-icon Revenue: $10 Million to $25 Million
  • tech-icon Active Tech Stack: See technologies

industries-icon Industry: Biotechnology

SIC SIC Code: 7372 | NAICS Code: 513210 | Show More

checked-icon Does something look wrong? Fix it. | View contact records from ORIONIS BIOSCIENCES

Orionis Biosciences Org Chart and Mapping

Employees

Ted Suh

Vice President, Chemistry

Craig Mackenzie

Senior Computational Biology Scientist

Jared Lopes

Director, Translational Biology at Orionis Biosciences

signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding Orionis Biosciences

Answer: Orionis Biosciences's headquarters are located at 950 Winter St, Waltham, , 2451, Massachusetts, United States

Answer: Orionis Biosciences's official website is https://orionisbio.com

Answer: Orionis Biosciences's revenue is $10 Million to $25 Million

Answer: Orionis Biosciences's SIC: 7372

Answer: Orionis Biosciences's NAICS: 513210

Answer: Orionis Biosciences has 11-50 employees

Answer: Orionis Biosciences is in Biotechnology

Answer: Orionis Biosciences contact info: Phone number: Website: https://orionisbio.com

Answer: Orionis Biosciences is a life sciences company pioneering technological innovation in genome-scale drug discovery and tunable molecular design of novel therapeutic drug modalities. Our technologies and pipeline include proprietary A-KineTM biologics and Allo-GlueTM small molecule platforms with broad, innovative applications to the reprogramming of disease states. The company is currently advancing multiple novel immunotherapies for the treatment of cancer.

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access